Phase 3 Heart Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are older than 18 and younger than 80 years of age.
• People who have been diagnosed with invasive breast cancer (stage I, II, or III) and who are planned to start a type of chemotherapy called anthracycline within 60 days.
• People who have signed a consent form agreeing to take part in the study.

Who may not be able to join:

• People who have a urinary tract infection requiring antibiotic treatment within 48 hours before the planned start of chemotherapy.
• People who have been diagnosed with heart failure, or who have symptoms that the trial doctor thinks could be signs of undiagnosed heart failure.
• People whose heart pumping strength (left ventricular ejection fraction) is below 50% at the time of screening.
• People who have a serious heart valve condition.
• People with a history of a significant abnormal heart rhythm, including atrial fibrillation of any type (at the trial doctor's judgment).
• People who have had a stroke.
• People who have any form of cardiomyopathy, which is a disease affecting the heart muscle (including inherited, post-inflammatory, toxic, or other specific types).
• People who have high blood pressure in the lungs (pulmonary hypertension).
• People with blood pressure that is not well controlled, or whose systolic blood pressure is below 80 mmHg at screening (at the trial doctor's judgment).
• People with a body mass index (BMI) above 40.
• People who have been diagnosed with type 1 or type 2 diabetes, or whose blood sugar levels at screening are above certain thresholds (confirm with trial site).
• People who are pregnant or breastfeeding.
• People who are not willing or able to use a highly effective form of contraception during the trial.
• People who are expected to receive specific types of chemotherapy drugs (epirubicin or liposomal doxorubicin) within 12 months.
• People who have taken another study drug, or a medication from a group called SGLT2 inhibitors, in the 6 months before the screening visit.
• People who have taken the medications semaglutide, liraglutide, or metformin in the 30 days before the screening visit.
• People whose kidneys are not filtering blood well enough, based on a specific kidney function test result (confirm with trial site).
• People whose cancer has spread to other parts of the body (stage IV), or whose life expectancy is less than 12 months.
• People whose liver enzyme levels (ALT or AST) are more than 2.5 times above the normal range.
• People who have anaemia with a haemoglobin level below 9 g/dl (a measure of low red blood cells).
• People with moderate to severe kidney failure (above a certain level on a standard kidney classification scale — confirm with trial site).
• People with liver problems above a certain level of severity (confirm with trial site).
• People with known, active infections including HIV, hepatitis B, hepatitis C, or tuberculosis.
• People with any other condition that, in the trial doctor's opinion, would make it impossible to safely participate in the study.

Important: Always verify eligibility with the trial site directly before applying.